Broad-Specificity Neutralizing Molecules for Influenza A Subtypes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating influenza A virus infections, particularly those caused by subtypes like H1, H3, and H5, are limited in their ability to provide broad protection against multiple strains and subtypes, posing a significant threat during epidemics and pandemics.
Innovation Solution
Development of neutralizing molecules, such as antibodies or antibody-like molecules, that can bind to multiple subtypes and isolates of influenza A virus, including H1, H3, and H5, without inhibiting hemagglutination, and can be used for passive immunization and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional influenza vaccines are used, then protection against specific influenza strains is provided, but protection is limited to one or a few subtypes and requires annual updates
Solution Approach 1:
The patent develops neutralizing molecules with broad specificity that can recognize and bind to multiple influenza A virus subtypes (H1, H3, H5, and other emerging subtypes) through a single molecular structure. This universal binding capability allows one vaccine formulation to provide protection against multiple subtypes simultaneously, eliminating the need for annual vaccine updates while maintaining reliable protection effectiveness.
Solution Approach 2:
The invention involves engineering antibody molecules with modified binding parameters - specifically designing neutralizing molecules that target conserved epitopes on the hemagglutinin protein that remain relatively unchanged across different influenza subtypes. By changing the binding parameters from subtype-specific variable regions to conserved region-specific binding, the molecule achieves broad cross-subtype neutralization while maintaining high affinity and protection effectiveness.
2Adaptability or versatility
If neutralizing molecules are designed to bind multiple subtypes, then broad protection is achieved, but specificity to particular viral epitopes must be maintained
Solution Approach 1:
The patent applies local quality by directing the neutralizing molecules to bind specifically to particular conserved epitopes on the hemagglutinin protein (such as the receptor binding site or stem region) while leaving other variable regions of the virus untouched. This localized binding to conserved functional regions ensures high binding specificity and effective neutralization across multiple subtypes without requiring the molecule to recognize all variable regions, thus maintaining precision while achieving breadth.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These molecules offer effective prevention and treatment options by neutralizing multiple strains of influenza A virus, providing broad protection against various subtypes and isolates, thereby reducing the risk and severity of infections during outbreaks.
Implementation Method 1
binds to a hemagglutinin (HA) antigen of the virus
Data Source
AI summary
The present invention concerns methods and means for identifying, producing, and engineering neutralizing molecules against influenza A viruses, and to the neutralizing molecules produced. In particular, the invention concerns neutralizing molecules against various influenza A virus subtypes, including neutralizing antibodies against H5 and/or H3 and/or H1, such as, for example all of H1, H3, and H5 subtypes, and methods and means for making such molecules.